


Market insights summary

# US obesity intervention market

## What's trending?


Rising adoption of GLP-1 RAs among the U.S. patient population

% GLP-1 RA prescriptions vs. bariatric surgery, U.S.



Temporary slowdown in U.S. bariatric procedures due to the rise of GLP-1 RAs

Bariatric surgery volumes, U.S.



GLP-1 receptor agonist (RA) prescriptions for obesity treatment surged in late 2022, driven by recent approvals for weight loss and their significant effectiveness. The popularity of the drugs have also been fueled by greater awareness due to celebrity influence.

Our Medtech 360 model forecasts lower growth compared to the previous report. Despite a stronger immediate impact, numbers are expected to stabilize and increase later due to the complementary use of bariatric surgery and GLP-1 RAs.

Access more insights and data in the [report](#).  
 Speak to our team to see how we can power your innovation.

GLP-1 RAs = Glucagon-like peptide-1 receptor agonists | ESG = endoscopic sleeve gastroplasty

## 2025 global market snapshot


**\$104M**

Market value


**1.0%**

CAGR ('19-'34)

### US obesity intervention market, by product type



### The growth of endoluminal procedures is outpacing traditional bariatric surgeries



### Robotic bariatric procedures are cannibalizing open and laparoscopic techniques

